Clinically significant pharmacokinetic drug interactions with carbamazepine

Clinical Pharmacokinetics

Volumn 31, Issue 3, 1996, Pages 198-214

  Spina, Edoardo ^a   Pisani, Franco ^a   Perucca, Emilio ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CIMETIDINE; CYTOCHROME P450; DANAZOL; DEXTROPROPOXYPHENE; DILTIAZEM; EPOXIDE HYDROLASE; ETHOSUXIMIDE; GLUCOCORTICOID; GLUCURONOSYLTRANSFERASE; ISONIAZID; MACROLIDE; METRONIDAZOLE; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROGABIDE; STIRIPENTOL; UNINDEXED DRUG; VALNOCTAMIDE; VALPROIC ACID; VALPROMIDE; VERAPAMIL;

BIPOLAR DEPRESSION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INDUCTION; ENZYME INHIBITION; EPILEPSY; HUMAN; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; TRIGEMINUS NEURALGIA;

EID: 0029815563     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631030-00004     Document Type: Review

References (214)

1. Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 1982; 7: 57-84
2. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic: drugs. Pharmacol Ther 1987; 33: 139-44
3. Perucca E, Richens A. Antiepileptic drug interactions. In: Janz D, Frey HH, editors. Antiepileptic drugs: handbook of experimental pharmacology. Vol. 74. Berlin: Springer-Verlag, 1985: 831-55
4. Perucca E, Richens A. Interactions between drugs used in the treatment of epilepsy. In: Pitlick WH, editor. Antiepileptic drug interactions. New York: Demos Publishers, 1989: 27-38
5. Baciewicz AM. Carbamazepine drug interactions. Ther Drug Monit 1986; 8: 305-17
6. Pisani F, Perucca E, Di Perri R. Clinically relevant anti-epileptic drug interactions. J Int Med Res 1990; 18: 1-15
7. Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine. Part I. J Clin Psychopharmacol 1991; 11: 198-203
8. Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine. Part II. J Clin Psychopharmacol 1991; 11: 306-13
9. Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 9: 156-84
10. Levy RH, Wurden CJ. Carbamazepine: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, editors. Anti-epileptic drugs. New York: Raven Press, 1995: 543-53
11. Anderson GD, Graves NM. Drug interactions with antiepileptic agents: prevention and management. CNS Drugs 1994; 2: 268-79
12. Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet 1978; 3: 128-43
13. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 1986; 11: 177-98
14. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47: 1969-79
15. Nebert DW, Nelson DR, Coon MJ, et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991; 10: 1-14
16. Johnson CM, Thummel KE, Kroetz DL, et al. Metabolism of CBZ by cytochrome P450 isoforms 3A4, 2C8 and 1A2. Pharm Res 1992; 9 Suppl.: 301
17. Eichelbaum M, Ekbom B, Bertilsson L, et al. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 1975; 8: 337-41
18. Pitlick WH, Levy RH, Troupin AS, et al. Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine. J Pharm Sci 1976; 65: 462
19. Bertilsson L, Hojer B, Tybring G, et al. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 1980; 27: 83-8
20. Neef C, Van Der Straaten V. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 1988; 43: 372-5
21. Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol 1980; 17: 51-7
22. Mattson GF, Mattson RH, Cramer JA. Interaction between valproic acid and carbamazepine: an in vitro study of protein binding. Ther Drug Monit 1982; 4: 181-4
23. Macphee GJA, Thompson GG, McInnes GT, et al. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1986; I: 700-3
24. Pisani F, Oteri G, Di Perri R. Valproic acid fails to displace phenobarbitone and carbamazepine from plasma protein binding sites in epileptic patients. Br J Clin Pharmacol 1981; 12: 81-3
25. McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Ther Drug Monit 1981; 3: 63-70
26. Brodie MJ, Forrest G, Rapeport WG. Carbamazepine-10,11-epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. Br J Clin Pharmacol 1983; 16: 747-50
27. Levy RH, Moreland TA, Morselli PL, et al. Carbamazepine/valproic acid interaction in man and rhesus monkey. Epilepsia 1984; 25: 338-45
28. Perucca E, Richens A. General principles: biotransformation. In: Levy RH, Mattson R, Meldrum B, et al., editors. Anti-epileptic drugs. 3rd ed. New York: Raven Press, 1989: 23-48
29. Pisani F, Fazio A, Oteri G, et al. Sodium valproate and valpromide: differential interaction with carbamazepine in epileptic patients. Epilepsia 1986; 27: 548-52
30. Pisani F, Caputo M, Fazio A, et al. Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. with valproate: a pharmacokinetic study. Epilepsia 1990; 31: 339-42
31. Meijer JWA, Binnie CD, Debets RMC, et al. Possible hazard of valpromide-carbamazepine combination therapy in epilepsy. Lancet 1984; I: 802
32. Levy RH, Kerr BM, Loiseau P, et al. Inhibition of carbamazepine epoxide elimination by valpromide and valproic acid. Epilepsia 1986; 27: 592
33. Pisani F, Fazio A, Oteri G, et al. Effect of valpromide on the pharmacokinetics of carbamazepine-10,11-epoxide. Br J Clin Pharmacol 1988; 25: 611-3
34. Kerr BM, Rettie AE, Eddy AC, et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther 1989; 46: 82-93
35. Pacifici GM, Tomson T, Bertilsson L, et al. Valpromide/carbamazepine and risk of teratogenicity. Lancet 1985; I: 397-8
36. Pacifici GM, Franchi M, Bencini C, et al. Valpromide inhibits human epoxide hydrolase. Br J Clin Pharmacol 1986; 22: 269-74
37. Pacifici GM, Rane A. Valpromide but not sodium hydrogen divalproate inhibits epoxide hydrolase in human liver. Pharmacol Toxicol 1987; 60: 237-8
38. Pisani F, Fazio A, Artesi C, et al. Impairment of carbamazepine-10,11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. Br J Clin Pharmacol 1992; 34: 85-7
39. Pisani F, Haj-Yehia A, Fazio A, et al. Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation. Epilepsia 1993; 34: 954-9
40. Graves NM, Ritter FJ, Wagner ML, et al. Effect of lamotrigine on carbamazepine epoxide concentrations. Epilepsia 1991; 32 Suppl. 3: 13
41. Warner T, Patsalos PN, Prevett M, et al. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992; 11: 147-50
42. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433-43
43. Pisani F, Xiao B, Fazio A, et al. Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. Epilepsy Res 1994; 19: 245-8
44. Leach JP, Blacklaw J, Stewart M, et al. Mutual pharmacokinetic interactions between remacemide hydrochloride and carbamazepine. Epilepsia 1995; 36 Suppl. 3: S163
45. Loiseau P, Tor J. Stiripentol in absence seizures. Epilepsia 1987; 28: 579
46. Levy RH, Loiseau P, Guyot M, et al. Effects of stiripentol on valproate plasma level and metabolism. Epilepsia 1987; 28: 605
47. Levy RH, Martinez-Lage M, Kerr BM, et al. Effect of stiripentol on the formation and elimination of carbamazepine epoxide [abstract no. 71]. 17th International Epilepsy Congress: 1987 Sep 6-11; Jerusalem
48. Kerr BM, Martinez-Lage JM, Viteri C, et al. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P450 inhibition by stiripentol. Epilepsia 1991; 32: 267-74
49. Kutt H, Solomon GE, Dhar AK, et al. Effects of progabide on carbamazepine epoxide and carbamazepine concentrations in plasma. Epilepsia 1984; 25: 684
50. Bianchetti G, Padovani P, Thenot JP, et al. Pharmacokinetic interactions of progabide with other antiepileptic drugs. Epilepsia 1987; 28: 68-73
51. Graves NM, Fuerst RH, Cloyd JC, et al. Progabide-induced changes in carbamazepine metabolism. Epilepsia 1988; 29: 775-80
52. Kroetz DL, Loiseau P, Guyot M, et al. In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide. Clin Pharmacol Ther 1993; 54: 485-97
53. McBride MC. Serum carbamazepine levels are increased by acetazolamide. Ann Neurol 1984; 16: 393
54. Munoz JJ, De Salamanca RH, Diaz-Obregon C, et al. The effect of clobazam on steady-state plasma concentrations of carbamazepine and its metabolites. Br J Clin Pharmacol 1990; 29: 763-5
55. Sackellares JC, Donofrio PD, Wagner JG, et al. Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulphonamide) in patients with refractory partial seizures. Epilepsia 1985; 26: 206-11
56. Browne TR, Szabo GK, Kres J, et al. Drug interactions of zonisamide (CI-912) with phenytoin and carbamazepine. J Clin Pharmacol 1986; 26: 555
57. Minami T, Ieiri I, Ohtsubo K, et al. Influence of additional therapy with zonisamide (Excegran) on protein binding and metabolism of carbamazepine. Epilepsia 1994; 35: 1023-5
58. Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990; 51: 126
59. Bonnet P, Vandel S, Nezelof S, et al. Carbamazepine, fluoxetine. Is there a pharmacokinetic interaction? Therapie 1992; 47: 165
60. Grimsley SR, Jann MW, Carter G, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991; 50: 10-5
61. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991; 84: 583-4
62. Martinelli V, Bocchetta A, Palmas AM, et al. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 1993; 36: 615-6
63. Joblin M, Ghose K. Possible interaction of sertraline with carbamazepine. N Z Med J 1994; 107: 43
64. Spina E, Avenoso A, Pollicino AM, et al. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993; 15: 247-50
65. Gidal BE, Anderson GD, Seaton TL, et al. Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther Drug Monit 1993; 15: 405-9
66. Andersen BB, Mikkelsen M, Vesterager A, et al. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 1991; 10: 201-4
67. Pisani F, Narbone MC, Fazio A, et al. Increased serum carbamazepine levels by viloxazine in epileptic patients. Epilepsia 1984; 25: 482-5
68. Pisani F, Fazio A, Oteri G, et al. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry 1986; 49: 1142-5
69. Dravet C, Mesdjian E, Cenraud B, et al. Interaction between carbamazepine and triacetyloleandomycin. Lancet 1977; 1: 810-1
70. Mesdjian E, Dravet C, Cenraud B, et al. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia 1980; 21: 489-96
71. Hedrick R, Williams F, Morin R, et al. Carbamazepine-erythromycin leading to carbamazepine toxicity in four epileptic children. Ther Drug Monit 1983; 5: 405-7
72. Vajda FJE, Bladin PF. Carbamazepine-erythromycin-base interaction [letter]. Med J Aust 1984; 140: 81
73. Carranco E, Kareus J, Co S, et al. Carbamazepine toxicity induced by concurrent erythromycin therapy. Arch Neurol 1985; 42: 187-8
74. Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther 1983; 33: 460-4
75. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450-82
76. Vincon G, Albin H, Demotes-Mainard F, et al. Effects of josamycin on carbamazepine kinetics. Eur J Clin Pharmacol 1987; 32: 321-3
77. Barzaghi N, Gatti C, Crema F, et al. Effect of flurithromycin, a new macrolide antibiotic, on carbymazepine disposition in normal subjects. Int J Clin Pharm Res 1988; 8: 101-5
78. O'Connor NK, Fris J. Clarithromycin-carbamanzepine interaction in a clinical setting. J Am Board Fam Pract 1994; 7: 489-492
79. Couet W, Istin B, Ingrand I, et al. Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine. Ther Drug Monit 1990; 12: 144-9
80. Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993; 34: 161-2
81. Rapeport WG, Dewland PM, Muirhead DC, et al. Lack of an interaction between azithromycin and carbamazepine [abstract]. Br J Clin Pharmacol 1992; 33: 551P
82. Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. BMJ 1982; 285: 261-2
83. Wright JM, Stokes FF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice versa. N Engl J Med 1982; 307: 1325-7
84. Block SH. Carbamazepine-isoniazid interaction. Pediatrics 1982; 69: 494-5
85. Fleenor ME, Harden JW, Curtis G. Interaction between carbamazepine and antitubercolosis agents. Chest 1991; 99: 1554
86. Patterson BD. Possible interaction between metronidazole and carbamazepine. Ann Pharmacother 1994; 28: 1303-4
87. Beattie B, Biller J, Melhaus B, et al. Verapamil-induced carbamazepine neurotoxicity. Eur Neurol 1988; 28: 104-5
88. Price WA, DiMarzio LR. Verapamil-carbamazepine neurotoxicity. J Clin Psychiatry 1988; 49: 80
89. Brodie MJ, Macphee GJA. Carbamazepine neurotoxicity precipitated by diltiazem. BMJ 1986; 292: 1170-1
90. Eimer M, Carter BL. Elevated serum carbamazepine concentrations following diltiazem initiation. Drug Intell Clin Pharm 1987; 21: 340-2
91. Ahmad S. Diltiazem-carbamazepine interaction. Am Heart J 1990; 120: 1485
92. Gadde K, Calabrese JR. Diltiazem effect on carbamazepine levels in manic depression. J Clin Psychopharmacol 1990; 10: 378-9
93. Bahls FH, Ozuna J, Ritchie DE. Interaction between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. Neurology 1991; 41: 740-2
94. Maoz E, Grossman E, Thaler M, et al. Carbamazepine neurotoxic reaction after administration of diltiazem. Arch Intern Med 1992; 152: 2503-4
95. Dam M, Kristensen B, Hansen SB, et al. Interaction between carbamazepine and propoxyphene in man. Acta Neurol Scand 1977; 56: 603-7
96. Dam M, Christiansen J. Interaction of propoxyphene with carbamazepine [letter]. Lancet 1977; 1: 509
97. Hansen BS, Dam M, Brandt J, et al. Influence of dextropropoxyphene on steady-state serum levels and protein binding of three anti-epileptic drugs in man. Acta Neurol Scand 1980; 61: 357-67
98. Oles KS, Mirza W, Penry JK. Catastrophic neurologic signs due to drug interaction: tegretol and darvon. Surg Neurol 1989; 32: 144-51
99. Telerman-Toppet N, Duret ME, Coers C. Cimetidine interaction with carbamazepine [letter]. Ann Intern Med 1981; 94: 544
100. Webster LK, Mihaly GW, Jones DB, et al. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol 1984; 27: 341-3
101. MacPhee GJA, Thompson GG, Scobie G, et al. Effect of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol 1984; 18: 411-9
102. Dalton MJ, Powell JR, Messenheimer JA. The influence of cimetidine on single dose carbamazepine pharmacokinetics. Epilepsia 1985; 26: 127-30
103. Sonne J, Luddorf K, Larsen NE, et al. Lack of interaction between cimetidine and carbamazepine. Acta Neurol Scand 1983; 68: 253-6
104. Levine M, Jones MV, Sheppard I. Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. Neurology 1985; 35: 562-5
105. Dalton MJ, Powell JR, Messenheimer JA. Cimetidine and carbamazepine: a complex pharmacokinetic interaction [abstract]. Drug Intell Clin Pharm 1985; 19: 456
106. Kramer G, Theisohn M, von Unruh GE, et al. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit 1986; 8: 387-92
107. Zielinsky JJ, Lichten EM, Haidukewych D. Clinically significant danazol-carbamazepine interaction. Ther Drug Monit 1987; 9: 24-7
108. Hayden M, Buchanan N. Danazol-carbamazepine interaction. Med J Aust 1991; 155: 851
109. Bourgeois BFD, Dodson WE, Ferrendelli JA. Interaction between primidone, carbamazepine, and nicotinamide. Neurology 1982; 32: 1122-6
110. Jann MW, Fidone GS. Effect of influenza vaccine on serum anticonvulsant concentrations. Clin Pharm 1986; 5: 817
111. Perucca E, Richens A. Reversal by phenytoin of carbamazepine-induced water intoxication: a pharmacokinetic interaction. J Neurol Neurosurg Psychiatry 1980; 43: 540-5
112. Christiansen J, Dam M. Influence of phenobarbital and diphenylidantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 1973; 49: 543-6
113. Schneider H. Carbamazepine: the influence of other anti-epileptic drugs on its serum levels. In: Schneider H, Janz D, Gardner-Thorpe C, et al., editors. Clinical pharmacology of antiepileptic drugs. Berlin: Springer-Verlag, 1975: 189-96
114. Johannessen SI, Strandjord RE. The influence of phenobarbital and phenytoin on carbamazepine serum levels. In: Schneider H, Janz D, Gardner-Thorpe C, et al., editors. Clinical pharmacology of antiepileptic drugs. Berlin: Springer-Verlag, 1975: 201-5
115. Cereghino JJ, Brock JT, Van Meter JC, et al. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975; 18: 733-41
116. Rane A, Hojer B, Wilson JT. Kinetics of carbamazepine and 10,11-epoxide metabolite in children. Clin Pharmacol Ther 1976; 19: 276-83
117. Lander CM, Eadie MJ, Tyrer JH. Factors influencing plasma carbamazepine concentration. Clin Exp Neurol 1977; 14: 184-93
118. Eichelbaum M, Kothe KW, Hoffman F. Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin Pharmacol Ther 1979; 26: 366-71
119. Battino D, Bossi L, Croci D, et al. Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy. Ther Drug Monit 1980; 2: 315-22
120. Zielinski JJ, Haidukewych D. Dual effects of carbamazepine-phenytoin interaction. Ther Drug Monit 1987; 9: 21-3
121. Tomson T, Spina E, Wedlund J-E. Minor additive inducing effects of phenobarbital on carbamazepine clearance in patients on combined carbamazepine-phenytoin therapy. Ther Drug Monit 1987; 9: 117-9
122. Dam M, Jensen A, Christiansen J. Plasma level and effect of carbamazepine in grand mal and psychomotor epilepsy. Acta Neurol Scand 1975; 60 Suppl.: 33-8
123. Korczyn AD, Ben-Zvi A, Kaplanski J, et al. Plasma levels of carbamazepine and metabolites: effect of enzyme inducers. In: Meinardi H, Rowan AJ, editors. Advances in epileptology. Amsterdam: Swets & Zeitlinger, 1978: 278-9
124. Westemberg HGM, van der Kleijn E, Oei TT, et al. Kinetics of carbamazepine and carbamazepine-epoxide determined by use of plasma and saliva. Clin Pharmacol Ther 1978; 23: 320-8
125. Bourgeois BFD, Wad N. Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children. Ther Drug Monit 1984; 6: 259-65
126. Eichelbaum M, Tomson T, Tybring G, et al. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin Pharmacokinet 1985; 10: 80-90
127. Spina E, Martines C, Fazio A, et al. Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an neuve metabolite of carbamazepine. Ther Drug Monit 1991; 13: 109-12
128. Kroetz DL, Kerr BM, McFarland LV, et al. Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. Clin Pharmacol Ther 1993; 53: 306-15
129. Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041-65
130. Albani F, Theodore WH, Washington P, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 1991; 32: 130-2
131. Wagner ML, Remmel RP, Graves NM, et al. Effect of felbamate on carbamazepine and its major metabolites. Clin Pharmacol Ther 1993; 53: 536-43
132. Perucca E, Richens A. Biotransformation. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 31-50
133. Wietholz H, Zysset T, Kreiten K, et al. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol 1989; 36: 401-6
134. Shaw PN, Houston JB, Rowland M, et al. Antipyrine metabolite kinetics in healthy human volunteers during multile dosing of phenytoin and carbamazepine. Br J Clin Pharmacol 1985; 20: 611-8
135. Hansen JM, Siersboeck-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971; 12: 539-43
136. Cereghino JJ, Van Meter JC, Brock JT, et al. Preliminary observations of serum carbamazepine concentrations in epileptic patients. Neurology 1973; 23: 357-66
137. Hooper WD, Dubetz DK, Eadie MJ, et al. Preliminary observations on the clinical pharmacology of carbamazepine. Proc Aust Assoc Neurol 1974; 11: 189-98
138. Windorfer A, Sauer W. Drug interactions during anticonvulsant therapy in childhood; diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepine and dipropylacetate. Neuropediatrics 1979; 8: 29-41
139. Lai ML, Lin TS, Huang JD. Effect of single-and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. Eur J Clin Pharmacol 1992; 43: 201-3
140. Browne TR, Evans JH, Szabo GK, et al. Effect of carbamazepine on phenytoin pharmacokinetics determined by a stable isotope technique. Neurology 1984; 35: 284
141. Browne TR, Szabo GK, Evans JH, et al. Carbamazepine increases phenytoin serum concentrations and reduces phenytoin clearance. Neurology 1988; 38: 1146-50
142. Coper H, von Herrath U. Pharmacokinetic investigation on the combination of diphenylhydantoin and carbamazepine. Epilepsia 1973; 14: 466-67
143. Lander CM, Eadie MJ, Tyrer JH. Interactions between anticonvulsants. Proc Aust Assoc Neurol 1975; 12: 111-6
144. Gratz ES, Theodore WH, Newmark ME, et al. Effect of carbamazepine on phenytoin clearance in patients with complex partial seizures. Neurology 1982; 32: A223
145. Zielinski JJ, Haidukewych D, Leheta BJ. Carbamazepine-phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication. Ther Drug Monit 1985; 7: 51-3
146. Callaghan N, Feely M, Daggan F, et al. The effect of anticonvulsant drugs which induce liver microsomal enzymes on derived and ingested phenobarbitone levels. Acta Neurol Scand 1977; 56: 1-7
147. Eadie MJ, Lander CM, Hooper WD, et al. Factors influencing phenobarbitone levels in epileptic patients. Br J Clin Pharmacol 1977; 4: 541-7
148. Warren JW, Benmaman JD, Wannamaker BB, et al. Kinetics of carbamazepine-ethosuximide interaction. Clin Pharmacol Ther 1980; 28: 646-51
149. Gatti G, Bartoli A, Marchiselli R, et al. Elevation of ethosuximide clearance in patients receiving concurrent treatment with enzyme inducing antiepileptic drugs [abstract no. 158]. First Congress of the European Association for Clinical Pharmacology and Therapeutics: 1995 Sep 27-30; Paris
150. Bowdle TA, Levy RH, Cutler RE. Effects of carbamazepine on valproic acid kinetics in normal subjects. Clin Pharmacol Ther 1979; 26: 624-34
151. Mihaly GW, Vajda FJ, Miles JL, et al. Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients. Eur J Clin Pharmacol 1979; 16: 23-9
152. Reunanen MI, Luoma P, Myllyla VV, et al. Low serum valproic acid concentrations in epileptic patients on combination therapy. Curr Ther Res Clin Exp 1980; 28: 456-62
153. Panesar SK, Orr JM, Farrel K, et al. The effect of carbamazepine on valproic acid disposition in adult volunteers. Br J Clin Pharmacol 1989; 27: 323-8
154. Perucca E, Gatti G, Frigo GM, et al. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978; 5: 445-9
155. Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990; 48: 225-35
156. Jann MW, Fidone GS, Israel MK, et al. Increased valproate serum concentrations upon carbamazepine cessation. Epilepsia 1988; 24: 578-81
157. Binnie CD, van Emde Boas W, Kastelijn-Nolste-Trenite DGA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986; 27: 248-4
158. Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: single dose pharmacokinetics and initial 1-week experience in refractory epilepsy. Epilepsy Res 1987; 1: 194-201
159. Doose DR, Gisclon LG, Liao S, et al. Pharmacokinetics of topiramate. Adv Antiepiletic Drug Ther 1995; 1: 7-16
160. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996. In press
161. Leppik IE, So E, Pask CA, et al. Pharmacokinetic study of tiagabine HCl in patients at multiple steady-state dose. Epilepsia 1993; 34 Suppl. 6: 355
162. Levy RH, Loiseau P, Guyot M, et al. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 1984; 36: 661-9
163. Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760-87
164. Ojemann LM, Shastri RA, Wilensky AJ, et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986; 8: 243-6
165. Rey E, Pons G, Olive G. Vigabatrin clinical pharmacokinetics. Clin Pharmacokinet 1992; 23: 267-78
166. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, editor. New trends in epilepsy management. London: Royal Society of Medicine Services Ltd, 1993: 41-6
167. Levy RH, Lane EA, Guyot M, et al. Analysis of parent drug-metabolite relationship in the presence of an inducer, application to the carbamazepine-clobazam interaction in normal man. Drug Metab Dispos 1983; 11: 286-92
168. Jawad S, Richens A. Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients. Br J Clin Pharmcol 1984; 18: 873-7
169. Bun H, Monjanel-Mouterde S, Noel F, et al. Effect of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethyclobazam. Pharmacol Toxicol 1990; 67: 136-40
170. Sennoune S, Mesdjian E, Bonneton J, et al. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 1992; 14: 269-74
171. Dhillon S, Richens A. Pharmacokinetics of diazepam in epileptic patients and normal volunteers following intravenous administration. Br J Clin Pharmacol 1981; 12: 841-4
172. Lai AA, Levy RH, Cutter RE. Time-course of interactions between carbamazepine and clonazepam. Clin Pharmacol Ther 1978; 25: 316-23
173. Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients on carbamazepine or phenytoin. Epilepsia 1996; 37: 253-7
174. Arana GW. Carbamazepine-induced reduction of plasma alprazolam concentrations: a clinical case report. J Clin Psychiatry 1988; 49: 448
175. Leinonen E, Lillsunde P, Laukkanen V, et al. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychopharmacol 1991; 11: 313-8
176. Jerling M, Bertilsson L, Sjoqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994; 16: 1-12
177. Perucca E, Manzo L, Crema A. Pharmacokinetic interactions between antiepileptic and psychotropic drugs. In: Trimble MR, editor. The psychopharmacology of epilepsy. Chichester: J Wiley and Sons Ltd, 1985: 95-105
178. Spina E, Perucca E. Newer and older antidepressants: a comparative review of drug interactions. CNS Drugs 1994; 2: 479-97
179. Spina E, Avenoso A, Campo GM, et al. The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology Berl 1995; 117: 413-6
180. Brosen K, Kragh-Sorensen P. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 1993; 15: 258-60
181. Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985; 5: 106-9
182. Kidron R, Averbuch I, Klein E, et al. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 1985; 20: 219-22
183. Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. Psychopharmacology (Berl) 1994; 116: 115-6
184. Linnoila, Viukari M, Vaisanen K, et al. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 1980; 13: 819-21
185. Balant-Gorgia EA, Balant LP. Therapeutic drug monitoring: relevance during the drug treatment of psychiatric disorders. CNS Drugs 1995; 4: 432-53
186. Raitasuo V, Lehtovaara R, Huttunen MO. Carbamazepine and plasma levels of clozapine. Am J Psychiatry 1993; 150: 169
187. Jerling M, Lindstrom L, Bonesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-74
188. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995; 29: 172-91
189. Rapport DJ, Calabrese JR. Interactions between carbamazepine and birth control pills. Psychosomatics 1989; 30: 462-4
190. Back DJ, Grimmer SFM, Orme MLE, et al. Evaluation of Committee on Safety of Medicine yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25: 527-32
191. Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30: 892-6
192. Jubiz W, Meikle AW. Alterations of glucocorticoid actions by other drugs and disease states. Clin Pharmacokinet 1979; 18: 113-21
193. Bartoszek M, Brenner M, Szefler SJ. Prednisotone and methyl-prednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther 1987; 42: 424-32
194. Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy and in women using low-dose oral contraceptives. Biomed Pharmacother 1986; 40: 301-10
195. Privitera MR. Interference by carbamazepine with dexamethasone suppression lest. Biol Psychiatry 1982; 17: 611
196. Ross JRY, Beeley L. Interaction between carbamazepine and warfarin. BMJ 1980; 2; 1415-6
197. Kendall AG, Boivin M. Warfarin-carbamazepine interaction. Ann Intern Med 1981; 94: 280
198. Massey EW. Effect of carbamazepine on coumadin metabolism. Ann Neurol 1983; 13: 691-2
199. Hansen JM, Siersbaeck-Nielsen K, Kristensen M, et al. Effect of diphenylhydantoin on the metabolism of dicoumarol in man. Acta Med Scand 1971; 189: 15-9
200. Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South Med J 1990; 83: 981
201. Lele P, Peterson P, Yang S, et al. Cyclosporin and tegretol: another drug interaction. Kidney Int 1985; 27: 344
202. Hillebrand G, Castro LA, van Scheidt, et al. Valproate for epilepsy in renal transplant recipients. Transplantation 1987; 43: 915-6
203. Alvarez JS, Del Castillo JAS, Ortiz MJA. Effect of carbamazepine on cyclosporin blood level. Nephron 1991; 58: 235-6
204. Szenohradszky J, Caldwell JE, Sharma ML, et al. Interaction of rocuronium (ORG9426) and phenytoin in a patient undergoing cadaver renal transplantation: a possible pharmacokinetic interaction? Anesthesiology 1994; 80: 1167-70
205. Alloul K, Varin F. Carbamazepine-induced changes in vecuronium pharmacokinetics in anaesthesized patients [abstract]. Clin Pharmacol Ther 1994; 55: 143
206. Melton AT, Antognini JF, Gronert CA. Prolonged duration of succinylcholine in patients receiving anticonvulsants: evidence for mild up-regulalion of acetylcholine receptors? Can J Anaesth 1993; 40: 939-42
207. Hassan M, Oberg G, Bjorkholm M, et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-6
208. Yue QT, Tomson T, Sawe J. Carbamazepine und cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 1994; 4: 193-8
209. Rodman JH, Murry DJ, Madded T, et al. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12: 2390-7
210. Templehoff R, Modica PA, Spitznagel EL. Anticonvulsant therapy increases fentanyl requirements during anesthesia for craniotomy. Can J Anaesth 1990; 37: 327-32
211. Bonay M, Jonville-Bera AP, Diot P, et al. Possible interaction between phenobarbital, carbamazepine, and itraconazole. Drug Saf 1993; 9: 309-11
212. Michelucci R, Cipolla G, Gatti G, et al. Reduction of nisoldipine bioavailability by induction of first-pass metabolism in epileptic patients. Epilepsia. In press
213. Bittencourt PRM, Gracia CM, Martins R, et al. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. Neurology 1992; 42: 492-6
214. Fleishacker JC, Hulst LK, Peters GR. The effect of phenytoin on the pharmacokineties of tirilazad mesylate in healthy male volunteers. Clin Pharmacol Ther 1994; 56: 389-97